+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Renal Denervation Devices Market by Technology (Micro-Infusion-Based, Pharmacologic Ablation, Radiofrequency-Based), Products (Catheters, Nerve Modifying Agents, RF Generator), Disease Application, End-User - Forecast 2023-2030

  • PDF Icon

    Report

  • 187 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5666635
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Renal Denervation Devices Market size was estimated at USD 210.13 million in 2022, USD 236.29 million in 2023, and is expected to grow at a CAGR of 13.52% to reach USD 579.85 million by 2030.

Renal denervation devices are medical tools that provide minimally invasive therapy for patients suffering from drug-resistant hypertension or high blood pressure that do not respond adequately to conventional pharmacological therapies. These devices offer an alternative solution by targeting the overactive sympathetic nerves surrounding the renal arteries, which play a crucial role in regulating blood pressure and contribute to the development of hypertension. The increasing prevalence of resistant hypertension among the global population due to lifestyle changes, rising awareness about the benefits of renal denervation procedures over conventional drug therapies, and the growing geriatric population are driving the renal denervation devices market growth. However, the high cost of renal denervation devices, associated procedures, and several stringent regulatory frameworks may hamper market growth. Technological advancements in device design and procedural techniques have improved efficacy and safety profiles for renal denervation treatments, which is expected to create a lucrative market opportunity.

Regional Insights

The Americas has a significant landscape in the renal denervation devices market due to a high prevalence of hypertension among its population and substantial investments in research for novel therapies. Advancements in technology and growing awareness about innovative treatment options amongst healthcare professionals have fueled demand for these devices. The EU shows significant potential for market growth owing to increased awareness about renal denervation therapy and favorable reimbursement policies across countries. Collaborative efforts on hypertension prevention and control have accelerated R&D initiatives in this domain. The MEA region holds promising opportunities for renal denervation devices due to a rising incidence of hypertension coupled with lifestyle changes and urbanization. In the APAC region, government funding and initiatives for hypertension research resulted in a growing number of clinical trials and patent filings. Robust healthcare infrastructure, a strong focus on technological advancements, increased awareness about hypertension management, and improved healthcare facilities have contributed to the region's renal denervation devices market growth.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Renal Denervation Devices Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Renal Denervation Devices Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Renal Denervation Devices Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Ablative Solutions, Inc., AngioDynamics, Inc., Aria CV, Inc., AtriCure, Inc., Bio-Heart, Boston Scientific Corporation, Cardinal Health, Inc., Kalos Medical, Medtronic PLC, Mercator MedSystems, Inc., Otsuka Holdings Co., Ltd., Shanghai Meiliweiye Medical Technology Co., Ltd., SoniVie, Symap Medical, Ltd., Symple Surgical, Inc., and Terumo Corporation.

Market Segmentation & Coverage

This research report categorizes the Renal Denervation Devices Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technology
    • Micro-Infusion-Based
    • Pharmacologic Ablation
    • Radiofrequency-Based
    • Ultrasound-Based
  • Products
    • Catheters
      • Multi Electrode Catheter
      • Single Electrode Catheter
    • Nerve Modifying Agents
    • RF Generator
  • Disease Application
    • Diabetes
    • Heart Failure
    • Hypertension
    • Renal Failure
  • End-User
    • Ambulatory Care Centers
    • Diagnostic Centers & Hospitals
    • Research & Academia
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Renal Denervation Devices Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Renal Denervation Devices Market?
  3. What are the technology trends and regulatory frameworks in the Renal Denervation Devices Market?
  4. What is the market share of the leading vendors in the Renal Denervation Devices Market?
  5. Which modes and strategic moves are suitable for entering the Renal Denervation Devices Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Renal Denervation Devices Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of congestive chronic renal failure with aging population
5.1.1.2. Growing adoption and inclination towards minimally invasive surgical procedures
5.1.2. Restraints
5.1.2.1. High cost associated with renal denervation devices
5.1.3. Opportunities
5.1.3.1. Technological advancements and improvements in renal denervation devices
5.1.3.2. Ongoing publishing of clinical guidelines for renal denervation and increasing clinical assessment studies
5.1.4. Challenges
5.1.4.1. Strict government regulations for product approval coupled with lack of experienced healthcare professionals
5.2. Market Segmentation Analysis
5.2.1. Technology: High adoption of ultrasound-based renal denervation technology
5.2.2. Product: Significant use of multi-electrode catheters for their shorter-time of procedures
5.2.3. Disease Application: Proliferating use of renal denervation devices for treating hypertension
5.2.4. End-User: Ambulatory care centers prioritize renal denervation devices as a minimally invasive and cost-effective solution
5.3. Market Trend Analysis
5.3.1. Favorable government approvals for renal denervation devices in the Americas backed by the presence of well-established medical device companies and rising medical professional acceptance
5.3.2. Expanding government support to improve diagnosis and treatment of hypertension coupled with increasing positive results from clinical trials of renal denervation devices in the APAC region
5.3.3. Supportive government initiatives and approval procedures for renal denervation devices across the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Renal Denervation Devices Market, by Technology
6.1. Introduction
6.2. Micro-Infusion-Based
6.3. Pharmacologic Ablation
6.4. Radiofrequency-Based
6.5. Ultrasound-Based
7. Renal Denervation Devices Market, by Products
7.1. Introduction
7.2. Catheters
7.3.1. Multi Electrode Catheter
7.3.2. Single Electrode Catheter
7.3. Nerve Modifying Agents
7.4. RF Generator
8. Renal Denervation Devices Market, by Disease Application
8.1. Introduction
8.2. Diabetes
8.3. Heart Failure
8.4. Hypertension
8.5. Renal Failure
9. Renal Denervation Devices Market, by End-User
9.1. Introduction
9.2. Ambulatory Care Centers
9.3. Diagnostic Centers & Hospitals
9.4. Research & Academia
10. Americas Renal Denervation Devices Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Renal Denervation Devices Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Renal Denervation Devices Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
13.3.1. Agreement, Collaboration, & Partnership
13.3.1.1. Clinical Accelerator Announces Collaboration with Verve Medical to Conduct an Early Human Feasibility Study for Treatment-Resistant Hypertension
13.3.2. New Product Launch & Enhancement
13.3.2.1. Renal Denervation Using Ultrasound Ablation in Treatment-Resistant Hypertension is Being Evaluated for Early Benefit Assessment in Germany
13.3.2.2. Transitional Coverage for Renal Denervation Catheter SYMPLICITY SPYRAL from Medtronic in France
13.3.2.3. SPYRAL HTN-ON MED Study Demonstrates Meaningful Clinical Benefits Consistent with other SPYRAL HTN Renal Denervation Trials
13.3.3. Investment & Funding
13.3.3.1. Korean Startup Kalos Gets USD 3.5 Million Grant to Develop Renal Denervation Device for hypertension Treatment
13.3.3.2. Andera Partners Invests in SoniVie, a Medtech Company Developing a Promising Device for the Treatment of Hypertension
13.3.3.3. Shanghai Golden Leaf Med Tec Co., Ltd Secures Hundreds of Mns of CNY in Series C Round
13.3.3.4. Ablative Solutions Raises USD 91.4 Million in Series D Financing Round
13.3.4. Award, Recognition, & Expansion
13.3.4.1. Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension
13.3.4.2. FDA Approves Verve Medical’s IDE Renal Pelvic Denervation Trial
13.3.4.3. SoniVie Receives IDE Approval from FDA for its Pilot Study to Treat Hypertension with its Renal Artery Denervation TIVUS Technology
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Abbott Laboratories
14.1.2. Ablative Solutions, Inc.
14.1.3. AngioDynamics, Inc.
14.1.4. Aria CV, Inc.
14.1.5. AtriCure, Inc.
14.1.6. Bio-Heart
14.1.7. Boston Scientific Corporation
14.1.8. Cardinal Health, Inc.
14.1.9. Kalos Medical
14.1.10. Medtronic PLC
14.1.11. Mercator MedSystems, Inc.
14.1.12. Otsuka Holdings Co., Ltd.
14.1.13. Shanghai Meiliweiye Medical Technology Co., Ltd.
14.1.14. SoniVie
14.1.15. Symap Medical, Ltd.
14.1.16. Symple Surgical, Inc.
14.1.17. Terumo Corporation
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
List of Figures
FIGURE 1. RENAL DENERVATION DEVICES MARKET RESEARCH PROCESS
FIGURE 2. RENAL DENERVATION DEVICES MARKET SIZE, 2022 VS 2030
FIGURE 3. RENAL DENERVATION DEVICES MARKET SIZE, 2018-2030 (USD THOUSAND)
FIGURE 4. RENAL DENERVATION DEVICES MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. RENAL DENERVATION DEVICES MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD THOUSAND)
FIGURE 6. RENAL DENERVATION DEVICES MARKET DYNAMICS
FIGURE 7. RENAL DENERVATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2022 VS 2030 (%)
FIGURE 8. RENAL DENERVATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2022 VS 2023 VS 2030 (USD THOUSAND)
FIGURE 9. RENAL DENERVATION DEVICES MARKET SIZE, BY PRODUCTS, 2022 VS 2030 (%)
FIGURE 10. RENAL DENERVATION DEVICES MARKET SIZE, BY PRODUCTS, 2022 VS 2023 VS 2030 (USD THOUSAND)
FIGURE 11. RENAL DENERVATION DEVICES MARKET SIZE, BY DISEASE APPLICATION, 2022 VS 2030 (%)
FIGURE 12. RENAL DENERVATION DEVICES MARKET SIZE, BY DISEASE APPLICATION, 2022 VS 2023 VS 2030 (USD THOUSAND)
FIGURE 13. RENAL DENERVATION DEVICES MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
FIGURE 14. RENAL DENERVATION DEVICES MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD THOUSAND)
FIGURE 15. AMERICAS RENAL DENERVATION DEVICES MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 16. AMERICAS RENAL DENERVATION DEVICES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD THOUSAND)
FIGURE 17. UNITED STATES RENAL DENERVATION DEVICES MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 18. UNITED STATES RENAL DENERVATION DEVICES MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD THOUSAND)
FIGURE 19. ASIA-PACIFIC RENAL DENERVATION DEVICES MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC RENAL DENERVATION DEVICES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD THOUSAND)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RENAL DENERVATION DEVICES MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA RENAL DENERVATION DEVICES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD THOUSAND)
FIGURE 23. RENAL DENERVATION DEVICES MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 24. RENAL DENERVATION DEVICES MARKET SHARE, BY KEY PLAYER, 2022

Companies Mentioned

  • Abbott Laboratories
  • Ablative Solutions, Inc.
  • AngioDynamics, Inc.
  • Aria CV, Inc.
  • AtriCure, Inc.
  • Bio-Heart
  • Boston Scientific Corporation
  • Cardinal Health, Inc.
  • Kalos Medical
  • Medtronic PLC
  • Mercator MedSystems, Inc.
  • Otsuka Holdings Co., Ltd.
  • Shanghai Meiliweiye Medical Technology Co., Ltd.
  • SoniVie
  • Symap Medical, Ltd.
  • Symple Surgical, Inc.
  • Terumo Corporation

Methodology

Loading
LOADING...

Table Information